ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Avnish Kapoor
Matched on OpenAlex author ID A5011132771. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
- Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-19-0597↗
- Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
- Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
- Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ronald Anthony Depinho · 6 shared papers, 2014–2026 · strength 0.45
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-19-0597↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Andrea Viale · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Piergiorgio Pettazzoni · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Huamin Wang · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Timothy Paul Heffernan · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Haoqiang Ying · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Wantong Yao · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Giulio Francesco Draetta · 5 shared papers, 2014–2026 · strength 0.35
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Alessandro Carugo · 4 shared papers, 2014–2026 · strength 0.33
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Jason B. Fleming · 4 shared papers, 2014–2026 · strength 0.33
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. DOI 10.1038/s41586-019-1062-1↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Giannicola Genovese · 3 shared papers, 2014–2026 · strength 0.26
- Paper Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/s41586-026-10488-6↗
- Paper Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic ca… DOI 10.1158/0008-5472.can-14-1854↗
- Paper Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. DOI 10.1038/nature13611↗
- Lewis C. Cantley · 2 shared papers, 2014–2026 · strength 0.23
- Ya’an Kang · 2 shared papers, 2014–2026 · strength 0.23
- Virginia Giuliani · 2 shared papers, 2014–2026 · strength 0.23
- Emanuela Brunetto · 2 shared papers, 2014–2026 · strength 0.23
- Alec C. Kimmelman · 2 shared papers, 2014–2026 · strength 0.23
- Costas Andreas Lyssiotis · 2 shared papers, 2014–2026 · strength 0.23
- Pingping Hou · 2 shared papers, 2019–2020 · strength 0.15
- Jianhua Zhang · 2 shared papers, 2014–2020 · strength 0.12
- Qiang Zhang · 1 shared paper, 2020 · strength 0.09
- Raghu Kalluri · 1 shared paper, 2020 · strength 0.09
- Yan Liang · 1 shared paper, 2019 · strength 0.06
- I-Lin Ho · 1 shared paper, 2019 · strength 0.06
- Jun Yao · 1 shared paper, 2019 · strength 0.06
- Johnathon Lynn Rose · 1 shared paper, 2019 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.